Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
A new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months in addition to other standard transplant medications such as prednisone.
Epistemonikos ID: 0f0edb8d2b4b1c78a2e70216619cd30020246fe9
First added on: May 04, 2024